Patents by Inventor Xiaoning ZHAO

Xiaoning ZHAO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-CD39 antibodies and use thereof
    Patent number: 11970543
    Abstract: Provided herein are anti-CD39 antibodies that inhibit the enzymatic activity of human CD39 and methods of using the same.
    Type: Grant
    Filed: March 2, 2023
    Date of Patent: April 30, 2024
    Assignees: ARCUS BIOSCIENCES, INC., WUXI BIOLOGICS IRELAND LIMITED
    Inventors: Christine Elizabeth Bowman, Ada Pei Xian Chen, Ester Fernandez-Salas, Nigel Pelham Clinton Walker, Xiaoning Zhao, Yaohua Hu, Siwei Nie, JijIe Gu
  • ANTI-CD39 ANTIBODIES AND USE THEREOF
    Publication number: 20240034803
    Abstract: Provided herein are anti-CD39 antibodies that inhibit the enzymatic activity of human CD39 and methods of using the same.
    Type: Application
    Filed: March 2, 2023
    Publication date: February 1, 2024
    Applicants: ARCUS BIOSCIENCES, INC., WUXI BIOLOGICS IRELAND LIMITED
    Inventors: Christine Elizabeth Bowman, Ada Pei Xian Chen, Ester Fernandez-Salas, Nigel Pelham Clinton Walker, Xiaoning Zhao, Yaohua Hu, Siwei Nie, Jijie Gu
  • Antibodies to TIGIT
    Patent number: 11820824
    Abstract: The present disclosure provides antibodies that specifically bind to TIGIT. The antibodies have the capacity for substantial activation of T cells and natural killer cells by inhibiting binding of TIGIT to CD155. The antibodies can be used for treatment of cancer and infectious disease, among other applications.
    Type: Grant
    Filed: June 1, 2021
    Date of Patent: November 21, 2023
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Kelsey Sivick Gauthier, Nigel Pelham Clinton Walker, Xiaoning Zhao, John Lippincott
  • ANTIBODIES TO TIGIT
    Publication number: 20220064294
    Abstract: The present disclosure provides antibodies that specifically bind to TIGIT. The antibodies have the capacity for substantial activation of T cells and natural killer cells by inhibiting binding of TIGIT to CD155. The antibodies can be used for treatment of cancer and infectious disease, among other applications.
    Type: Application
    Filed: June 1, 2021
    Publication date: March 3, 2022
    Inventors: Kelsey Sivick GAUTHIER, Nigel Pelham Clinton WALKER, Xiaoning ZHAO, John LIPPINCOTT